Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation

Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring.

Download Full-text

Effect of Therapy with Recombinant Human Growth Hormone on Insulin-Like Growth Factor System Components and Serum Levels of Biochemical Markers of Bone Formation in Children After Severe Burn Injury1

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.83.1.4518 ◽

1998 ◽

Vol 83 (1) ◽

pp. 21-24 ◽

Cited By ~ 1

Author(s):

Gordon L. Klein ◽

Steven E. Wolf ◽

Craig B. Langman ◽

Clifford J. Rosen ◽

Subburaman Mohan ◽

...

Keyword(s):

Wound Healing ◽

Growth Factor ◽

Bone Formation ◽

Binding Protein ◽

Serum Levels ◽

Controlled Study ◽

Type I ◽

Insulin Like Growth Factor ◽

Type I Procollagen ◽

Igfbp 3

Burn injury in children is associated with low bone formation and long-term bone loss. Because recombinant human GH (rHGH) may accelerate burn wound healing, and because rHGH increases bone formation and density in GH-deficient patients, we studied the short-term effects of rHGH on bone formation, reflected by osteocalcin and type I procollagen propeptide levels in a randomized, double-blind, placebo-controlled study. Nineteen patients were enrolled and received either rHGH (0.2 mg/kg·day) or an equal volume of saline. Mean burn size and age were not different between the groups, and test substances were given from admission to time of wound healing (mean: 43 ± 22 days). At wound healing, serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 in the rHGH group rose to mean values of 229% and 187% of the respective means of the placebo group (P < 0.025). Serum osteocalcin concentrations remained below normal in both groups, and type I procollagen propeptide levels achieved a low normal level. IGFBP-4 levels were twice that of normal on admission and doubled further at wound healing; IGFBP-5 levels were low on admission but rose to normal at wound healing. We conclude that large doses of rHGH were ineffective in improving disordered bone formation despite increasing serum IGF-1 and IGFBP-3. The rHGH-independent rise in serum levels of the inhibitory binding protein IGFBP-4 suggests a mechanism by which improved bone formation is prevented despite successful elevation of IGF-1 and IGFBP-3 in the burned child.

Download Full-text

Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta

Clinical Chemistry ◽

10.1373/clinchem.2006.083055 ◽

2007 ◽

Vol 53 (6) ◽

pp. 1109-1114 ◽

Cited By ~ 15

Author(s):

Tim Cundy ◽

Anne Horne ◽

Mark Bolland ◽

Greg Gamble ◽

James Davidson

Keyword(s):

Alkaline Phosphatase ◽

Bone Formation ◽

Bone Mass ◽

Osteogenesis Imperfecta ◽

Plasma Concentrations ◽

Bone Alkaline Phosphatase ◽

Type I ◽

Low Bone Mass ◽

Bone Formation Markers ◽

Discriminant Ability

Abstract Background: Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults. Methods: We measured plasma concentrations of procollagen-1 N-peptide (P1NP), osteocalcin, and bone alkaline phosphatase in 24 patients with nondeforming OI, 25 patients with low bone mass due to other causes, and 38 age- and sex-matched controls. The discriminant ability of various test combinations was assessed by the construction of ROC curves. Results: The median (range) ratio of osteocalcin to P1NP was significantly greater in patients with type I OI [1.75 (0.80–3.86)] than in controls [0.59 (0.34–0.90)] and patients with other causes of low bone mass [0.48 (0.05–1.38); P <0.0001]. This ratio allowed nearly complete differentiation between healthy controls and patients with type I OI, but not patients with type IV OI. With a cutoff of 0.97 for osteocalcin:P1NP, the sensitivity and specificity were maximized at 95% (95% CI 76%–100%) and 88% (69%–97%), respectively, for patients with other causes of low bone mass vs those with type I OI only. For patients with other causes of low bone mass vs all OI patients, sensitivity and specificity were 83% (63%–95%) and 88% (69%–97%), respectively. The addition of bone alkaline phosphatase data did not improve the discriminant ability of the osteocalcin:P1NP ratio. Conclusions: The osteocalcin:P1NP ratio is a sensitive and specific test for type I OI in adults, but it has less utility in the diagnosis of other types of nondeforming OI.

Download Full-text

Effect of Adjuvant Chemotherapy is Responsible for Decreasing Segmental and Total BMD in BC Postmenopausal Women

Cancer Research and Cellular Therapeutics ◽

10.31579/2640-1053/021 ◽

2018 ◽

Vol 2 (1) ◽

pp. 01-05

Author(s):

Srileela Movva ◽

Srinivasa Rao Konijeti

Keyword(s):

Breast Cancer ◽

Alkaline Phosphatase ◽

Adjuvant Chemotherapy ◽

Bone Formation ◽

Biochemical Markers ◽

Type I ◽

Mineral Density ◽

Before And After ◽

Egyptian Women ◽

Markers Of Bone Formation

Background: Women with breast cancer are at increased risk for the development of osteoporosis and skeletal fractures, as consequences of aromatase inhibition or chemotherapy-induced ovarian failure. We investigated the effect of adjuvant chemotherapy on biochemical markers of bone formation and resorption as well as on bone mineral density (BMD) of non-metastatic breast cancer (NMBC) postmenopausal Egyptian women. Methods: We followed 100 newly diagnosed women with T1-3 N0-2 M0 breast cancer, who had a mean age (±SD) of 55.06±8.78 year, before and after receiving 6-cycles of CAF chemotherapy treatment protocol. All participant women were subjected to blood biochemical analysis for determining serum levels of: erythrocyte sedimentation rate, calcium, alkaline phosphatase (ALP), bone specific alkaline phosphatase (S.ALP), Osteocalcin, carboxytelopeptide of collagen type I (CTx-I), 25-Hydroxyvitamin D, Parathyroid Hormone (PTH) and tumor marker CA15-3. Segmental and total BMD were also investigated using Dual X-ray Absorptiometry technique. Results: We found ALP, S.ALP, and CTx-I levels were significantly lower (p<0.001), while PTH levels to be significantly higher for all women after chemotherapy as compared to their initial state before chemotherapy. Both segmental and total BMD, and consequently T- and Z-Scores after chemotherapy were significantly (p<0.01) lower than their levels before chemotherapy. We developed prediction mathematical formulae for spine, pelvis and total BMD for all women before and after chemotherapy. Conclusions: Adjuvant chemotherapy is responsible for decreasing both biochemical markers of bone formation and resorption as well as for decreasing segmental and total BMD in NMBC postmenopausal Egyptian women. We believe the mathematical formulae developed on basis of the two individual variables Age and BMI can be useful for assisting the clinician to frequently monitor bone health status of breast cancer patients in similar conditions.

Download Full-text

Relationship between Bone Formation Markers Bone Alkaline Phosphatase, Osteocalcin and Amino-Terminal Propeptide of Type I Collagen, and Bone Mineral Density in Elderly Men: Preliminary Results

10.1210/endo-meetings.2011.part3.p23.p3-139 ◽

2011 ◽

pp. P3-139-P3-139

Author(s):

Franco Lumachi ◽

Stefano MM Basso ◽

Piero Cappelletti ◽

Rocco Orlando

Keyword(s):

Bone Mineral Density ◽

Alkaline Phosphatase ◽

Bone Formation ◽

Type I Collagen ◽

Bone Alkaline Phosphatase ◽

Type I ◽

Mineral Density ◽

Preliminary Results ◽

Amino Terminal ◽

Bone Formation Markers

Download Full-text

Prediction of Bone Mass in Renal Hyperparathyroidism by Newly Developed Bone Metabolic Markers: Evaluation of Serum Levels of Carboxy-Terminal Pyridinoline Cross-Linked Telopeptide of Type I Collagen and Carboxy-Terminal Propeptide of Type I Procollagen

World Journal of Surgery ◽

10.1007/s002689900114 ◽

1996 ◽

Vol 20 (7) ◽

pp. 753-757 ◽

Cited By ~ 9

Author(s):

Makoto Katagiri ◽

Masao Fukunaga ◽

Takahiro Ohtawa ◽

Tanekazu Harada

Keyword(s):

Bone Mass ◽

Type I Collagen ◽

Serum Levels ◽

Type I ◽

Renal Hyperparathyroidism ◽

Bone Metabolic Markers ◽

Metabolic Markers ◽

Type I Procollagen ◽

Carboxy Terminal

Download Full-text

Possible variation in bone resorption during the normal menstrual cycle

Acta Endocrinologica ◽

10.1530/acta.0.1290388 ◽

1993 ◽

Vol 129 (5) ◽

pp. 388-392 ◽

Cited By ~ 25

Author(s):

Annette Schlemmer ◽

Christian Hassager ◽

Juha Risteli ◽

Leila Risteli ◽

Signe B Jensen ◽

...

Keyword(s):

Menstrual Cycle ◽

Bone Resorption ◽

Bone Formation ◽

Biochemical Markers ◽

Premenopausal Women ◽

Type I ◽

Normal Menstrual Cycle ◽

Cyclic Changes ◽

Carboxy Terminal ◽

Markers Of Bone Formation

In order to determine whether bone turnover varies during the normal menstrual cycle, we measured biochemical markers of bone resorption (serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (sICTP), fasting urinary hydroxyproline/creatinine, fasting urinary pyridinoline/creatinine and fasting urinary deoxypyridinoline/creatinine) and bone formation (plasma osteocalcin, serum carboxy-terminal propeptide of type I procollagen and serum alkaline phosphatase) in ten healthy premenopausal women every two or three days for a complete menstrual cycle. A cyclic pattern was detected in sICTP, with its nadir during the follicular phase and its peak during the luteal phase, and an overall variation of 17% during the menstrual cycle (p = 0.004). No cyclic changes were observed in the urinary parameters of bone resorption or in the biochemical markers of bone formation. We conclude that sICTP, a new biochemical marker of bone resorption, undergoes small variations during a normal menstrual cycle in premenopausal women, whereas the biochemical markers of bone formation remain constant.

Download Full-text